All In Biotech

Drug Trial Radar · NCT00642902

A Phase 2 Study of Atacicept in Subjects With Relapsing Multiple Sclerosis (ATAMS)

A Four-Arm Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study to Evaluate the Safety, Tolerability and Efficacy as Assessed by Frequent MRI Measures of 3 Doses of Atacicept Monotherapy in Subjects With Relapsing Multiple Sclerosis (RMS) Over a 36 Week Treatment Course

Last checked: Nov 20, 2026Latest source record: May 24, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingRandomized with 255 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

255

Actual

Start

Apr 2008

Primary completion

Sep 2009

Study completion Sep 2009

Sponsor

Lead sponsor
EMD SeronoIndustry
Sponsor type
Industry
First posted
Mar 25, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the safety and tolerability of atacicept and to explore if atacicept reduces central nervous system inflammation in subjects with relapsing multiple sclerosis (RMS) as assessed by frequent magnetic resonance imaging (MRI). This study is randomised. Study medication is administered via subcutaneous (under the skin) injections.

Conditions

  • Relapsing Multiple Sclerosis

Interventions

  • AtaciceptDrug

    Atacicept will be administered subcutaneously at a dose of 25 milligram (mg) twice a week for initial 4 weeks as loading dose, followed by 25 mg once a week for subsequent 32 weeks.

  • AtaciceptDrug

    Atacicept will be administered subcutaneously at a dose of 75 mg twice a week for initial 4 weeks as loading dose, followed by 75 mg once a week for subsequent 32 weeks.

  • AtaciceptDrug

    Atacicept will be administered subcutaneously at a dose of 150 mg twice a week for initial 4 weeks as loading dose, followed by 150 mg once a week for subsequent 32 weeks.

  • Placebo matched to ataciceptDrug

    Placebo matched to atacicept will be administered subcutaneously twice a week for initial 4 weeks, followed by once a week for subsequent 32 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean Number of Time Constant 1 (T1) Gadolinium (Gd)-Enhancing Lesions Per Participant Per ScanTime frame: Weeks 12 to 36

Locations

50 sites in 17 countries. Site status is shown where the registry gives one.

  • Research Site

    Phoenix, Arizona

  • Research Site

    Atlanta, Georgia

  • Research Site

    Northbrook, Illinois

  • Research Site

    East Lansing, Michigan

  • Research Site

    Jefferson, New Hampshire

  • Research Site

    Cleveland, Ohio

  • Site not named

    Philadelphia, Pennsylvania

  • Research Site

    Nashville, Tennessee

  • Research Site

    Box Hill, Australia

  • Research Site

    Fitzroy, Australia

  • Research Site

    New Lambton, Australia

  • Research Site

    Woodville, Australia

  • Research Site

    Innsbruck, Austria

  • Research Site

    Diepenbeek, Belgium

  • Research Site

    Sijsele, Belgium

  • Research Site

    Ontario, Canada

  • Research Site

    Calgary, Alberta, Canada

  • Research Site

    Ottawa, Ontario, Canada

  • Research Site

    Brno, Czechia

  • Research Site

    Hradec Králové, Czechia

  • Research Site

    Olomouc, Czechia

  • Research Site

    Caen, France

  • Research Site

    Saint-Herblain, France

  • Research Site

    Bochum, Germany

  • Research Site

    Düsseldorf, Germany

  • Research Site

    Beirut, Lebanon

  • Research Site

    Kaunas, Lithuania

  • Research Site

    Breda, Netherlands

  • Research Site

    Nieuwegein, Netherlands

  • Research Site

    Rotterdam, Netherlands

  • Research Site

    Dnipropetrovsk, Russia

  • Research Site

    Moscow, Russia

  • Research Site

    Novosibirsk, Russia

  • Research Site

    Saint Petersburg, Russia

  • Research Site

    Samara, Russia

  • Research Site

    Vladimir, Russia

  • Research Site

    Yaroslavl, Russia

  • Research Site

    Yekaterinburg, Russia

  • Research Site

    Barcelona, Spain

  • Research Site

    Madrid, Spain

Showing 40 of 50 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.